Sugi Predict

Sugi Predict / Compounds / SCHEMBL441127

SCHEMBL441127

SCHEMBL441127

Cc1cn([C@H]2CN(C(c3ccccc3)(c3ccccc3)c3ccccc3)C[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ RNASE1 P07998 1/20 0.50
▸ TK2 O00142 3/20 0.49
▸ TK1 P04183 7/20 0.48
▸ LMNA P02545 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ ALB P02768 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ PMP22 Q01453 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409820 1.00 RNASE1 (0.50) RNASE1TK2TK1LMNATSHR
SCHEMBL19660825 0.91 TK1 (0.45) RNASE1TK2TK1
SCHEMBL19953995 0.90 TK1 (0.44) RNASE1TK2TK1
SCHEMBL27157713 0.89 TYMP (0.48) RNASE1TK2TK1
SCHEMBL31000070 0.89 TK1 (0.49) RNASE1TK2TK1TSHRBLM
SCHEMBL14968223 0.86 TK1 (0.44) RNASE1TK2TK1
SCHEMBL9978645 0.86 TK1 (0.44) RNASE1TK2TK1
SCHEMBL409970 0.86 RNASE1 (0.42) RNASE1TK2TK1
SCHEMBL9978644 0.85 TK1 (0.43) RNASE1TK2TK1
SCHEMBL14968221 0.85 TK1 (0.43) RNASE1TK2TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600744-B2 Method for producing oligonucleic acid compound NIPPON SHINYAKU CO., LTD. (JP) 2026-04-14 — — US disclosed
US-12600743-B2 Method for producing oligonucleic acid compound NIPPON SHINYAKU CO., LTD. (JP) 2026-04-14 — — US disclosed
EP-4596047-A2 ANTISENSE NUCLEIC ACID FOR USE IN TREATING DUCHENNE MUSCULAR DYSTROPHY Nippon Shinyaku Co., Ltd. (JP) 2025-08-06 — — EP disclosed
US-20250188459-A1 Antisense Nucleic Acids NIPPON SHINYAKU CO., LTD. (JP) 2025-06-12 — — US disclosed
EP-3660154-B1 ANTISENSE NUCLEIC ACID FOR USE IN TREATING DUCHENNE MUSCULAR DYSTROPHY NIPPON SHINYAKU CO LTD (JP) 2025-04-16 — — EP disclosed
US-20250084412-A1 Antisense Nucleic Acids NIPPON SHINYAKU CO., LTD. (JP) 2025-03-13 — — US disclosed
US-20250042933-A1 ANTISENSE NUCLEIC ACIDS NIPPON SHINYAKU CO., LTD. (JP) 2025-02-06 — — US disclosed
US-20240368597-A1 Antisense Nucleic Acids NIPPON SHINYAKU CO., LTD. (JP) 2024-11-07 — — US disclosed
US-12060556-B2 Antisense nucleic acids NIPPON SHINYAKU CO., LTD. (JP) 2024-08-13 — — US disclosed
CN-113913426-B Antisense nucleic acid 日本新药株式会社 2024-08-02 — — CN disclosed
US-8779128-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2014-07-15 — — US disclosed
EP-2704749-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES Sarepta Therapeutics, Inc. (US) 2014-03-12 — — EP disclosed
US-20130211062-A1 ANTISENSE NUCLEIC ACIDS NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) 2013-08-15 — — US disclosed
EP-2612917-A1 ANTISENSE NUCLEIC ACID Nippon Shinyaku Co., Ltd. (JP) 2013-07-10 — — EP disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 — — WO disclosed
EP-2576574-A2 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS Sarepta Therapeutics, Inc. (US) 2013-04-10 — — EP disclosed
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES AVI BIOPHARMA, INC. (US) 2012-11-15 — — US disclosed
WO-2012150960-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES AVI BIOPHARMA, INC. (US) 2012-11-08 — — WO disclosed
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2012-03-15 — — US disclosed
WO-2011150408-A2 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS AVI BIOPHARMA, INC. (US) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB RNASE1 79/4885TK2 489/4885TK1 559/4885
US-20240368597-A1 Antisense Nucleic Acids UTRN, RBM17, UPF1 RNASE1 397/4885TK2 1475/4885TK1 1759/4885
US-12600743-B2 Method for producing oligonucleic acid compound SUB1, CTDSP1, POLR1A RNASE1 176/4885TK2 251/4885TK1 166/4885
US-20250084412-A1 Antisense Nucleic Acids UPF1, NSUN2, NSUN3 RNASE1 64/4885TK2 445/4885TK1 558/4885
US-12060556-B2 Antisense nucleic acids UPF1, NSUN2, NSUN3 RNASE1 64/4885TK2 445/4885TK1 558/4885
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES SNRPE, SMN1; SMN2, UPF1 RNASE1 9/4885TK2 419/4885TK1 217/4885
US-20130211062-A1 ANTISENSE NUCLEIC ACIDS UTRN, RBM17, UPF1 RNASE1 265/4885TK2 634/4885TK1 1611/4885
US-12600744-B2 Method for producing oligonucleic acid compound NSUN2, SUB1, RPA1 RNASE1 40/4885TK2 379/4885TK1 170/4885
US-20250042933-A1 ANTISENSE NUCLEIC ACIDS UTRN, RBM17, UPF1 RNASE1 265/4885TK2 634/4885TK1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.